MétaCan
Menu
Back to cohort
Record W4210926374 · doi:10.21203/rs.3.rs-1321818/v1

Tolerability of Eribulin and Correlation Between Polymorphisms and Neuropathy in an Unselected Population of Female Patients with Metastatic Breast Cancer: Results of The Multicenter, Single Arm, Phase IV PAINTER Study

2022· preprint· en· W4210926374 on OpenAlexaff
Nicla La Verde, Giovanna Damia, Ornella Garrone, Daniele Santini, Alessandra Fabi, Mariangela Ciccarese, Daniele Generali, Martina Nunzi, Elena Poletto, Elisa Ferraris, Elisabetta Cretella, Giuseppa Scandurra, Icro Meattini, Alessandro Bertolini, Luigi Cavanna, Elena Collovà, Emanuela Romagnoli, Eliana Rulli, Lorenzo Legramandi, Federica Guffanti, Annalisa Bramati, Anna Moretti, Alessandra Cassano, Patrizia Vici, Valter Torri, Gabriella Farina

Bibliographic record

VenueResearch Square · 2022
Typepreprint
Languageen
FieldMedicine
TopicCancer Treatment and Pharmacology
Canadian institutionsUniversity Hospital Foundation
Fundersnot available
KeywordsMedicineTolerabilityEribulinInternal medicineNeutropeniaMetastatic breast cancerGastroenterologyBreast cancerAdverse effectFebrile neutropeniaOncologySurgeryCancerToxicity

Abstract

fetched live from OpenAlex

Abstract BACKGROUNDMetastatic breast cancer (MBC) is an incurable disease and its treatment focuses on prolonging patients (pts) overall survival (OS) and improving their quality of life. eribulin is a microtubule inhibitor that increases OS in pre-treated MBC pts. Its common adverse events (AEs) are asthenia, neutropenia and peripheral neuropathy (PN).METHODSThe PAINTER is a single arm, phase IV study, aimed at surveying eribulin tolerability in MBC pts. Secondary objectives were to explore incidence and severity of PN, its association with genetic polymorphisms, and the description of treatment efficacy and safety. Genomic DNA was isolated from blood samples and 15 Single Nucleotide Polymorphisms (SNPs) were genotyped by Taqman specific assays. The associations between PN and SNPs were evaluated by Fisher exact test.RESULTSFrom May 2014 to June 2018 180 pts were enrolled from 20 Italian centers; 170 were evaluable for efficacy and toxicity and 159 for polymorphisms analysis. Median age was 60 years, biological subtypes were luminal type (64.7%), Her2 positive (18.3%) and triple negative (17%). Pts were pretreated with a median of 5 lines for MBC. With a median follow up of 15.4 months, a median number of eribulin cycles of 4.5 (minimum-maximum 1-23), median overall survival was 12 months. 48.8% of pts experienced dose reduction, mainly for neutropenia (23.9%) and liver injury (12%). 65 pts (38.2%) reported at least one severe toxicity. Neutropenia and neurotoxicity were the most frequent severe AEs (15.3% and 14.7% respectively); other toxicities were osteo-muscular, abdominal or tumor site pain (19.4%), liver injury (6.6%), pulmonary toxicity (6.5%) and dermatological (3.6%), Among the 15 evaluated SNPs, an association with PN was found for rs2233335 and rs7214723. CONCLUSIONSEribulin is a well-tolerated treatment in MBC. Schedule and dosage modifications were common, but toxicity rarely led to treatment discontinuation. SNPs rs2233335 (G/T and T/T) in NDRG1 gene and rs7214723 (CC and CT) in CAMKK1 gene were associated with PN. These findings, if validated, could allow a tailored eribulin treatment in cancer patients.Trial registration: ClinicalTrials.gov ID: NCT02864030EudraCT: 2013-004600-19

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Non-randomized trial · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.001
Threshold uncertainty score0.005

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.068
GPT teacher head0.416
Teacher spread0.348 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNon-randomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2022
Admission routes1
Has abstractyes

Explore more

Same venueResearch SquareSame topicCancer Treatment and PharmacologyFrench-language works237,207